Ventaris Surgical Secures $30 Million in Series A Funding to Revolutionize Kidney Stone Treatment Technology

Ventaris Surgical's Major Milestone in Medical Innovation

On January 9, 2026, Ventaris Surgical, Inc., a pioneering medical device company based in San Carlos, California, announced the successful completion of a $30 million Series A financing round. This significant funding is set to propel the development of their next-generation ureteroscopic system designed for kidney stone treatment. The financing was led by Longitude Capital, who was joined by Vensana Capital, alongside existing investors such as Atypical Ventures, Neotribe Ventures, and Boutique Venture Partners.

The incorporation of industry leaders into the board, including Varun Gupta from Longitude Capital and Justin Klein from Vensana, highlights the confidence and expectations surrounding Ventaris Surgical's innovative approach. The company aims to address prevailing challenges in kidney stone surgery, which remains one of the most prevalent urologic procedures worldwide. Current obstacles faced during surgeries include varied anatomical structures, the complexity of stone burdens, workflow inefficiencies, and, importantly, surgeon fatigue. These factors have contributed to inconsistent stone clearance outcomes, leaving a critical demand for improved surgical tools.

Transforming Kidney Stone Surgery

"Ventaris' technology has the potential to both improve outcomes and reduce the burden on surgeons. Their approach resolves several critical unmet needs in today's standard of care," stated Maxwell Bikoff, Managing Director at Longitude Capital. This underscores a strong belief in the capability of Ventaris' innovations to revolutionize the existing standards of care in urology.

Surag Mantri, CEO of Ventaris Surgical, emphasized the core challenge of achieving full stone clearance during procedures which requires immense skill, focus, and dedication from surgeons. He explained that while many surgeons strive diligently for complete clearance of stones, the current surgical tools often complicate this aspiration. Ventaris Surgical emerged with a mission to eliminate these barriers, facilitating a more straightforward pathway for surgeons to attain successful outcomes. With the recent funding bolstering their development plans, Ventaris is enthusiastic about embarking on this crucial growth phase.

Strategic Use of Financing Proceeds

The capital raised from this financing round will significantly accelerate Ventaris Surgical's journey towards clinical development alongside aiding in regulatory approvals and commercial engagements. The ultimate goal remains to increase the efficiency of kidney stone interventions, promising a future where medical professionals can better serve their patients with a streamlined and effective approach.

About Ventaris Surgical

As a company dedicated to medical advancements, Ventaris Surgical is focused on creating a ureteroscopic system specifically designed for complete stone clearance in kidney stone surgeries. Aligned with their innovation vision, Ventaris strives to lead the charge in transforming the surgical landscape in urology, optimizing processes that currently hinder procedure success rates.

For more information about Ventaris Surgical and their groundbreaking medical devices, interested parties can visit their official website at ventarissurgical.com. They are committed to improving patient outcomes by modernizing and enhancing surgical procedures through cutting-edge technology that meets healthcare practitioners' real needs.

About Longitude Capital and Vensana Capital

Longitude Capital is recognized for its venture growth investments in the biotechnology and tech-enabled healthcare sectors, boasting over $2.4 billion raised to date. Their strong portfolio indicates a commitment to nurturing innovative healthcare solutions. Meanwhile, Vensana Capital has emerged as a vital partner for entrepreneurs across the medtech space, focusing on transformative medical technology firms. With approximately $1 billion under management, Vensana is dedicated to fostering advancements that could reshape patient care in medical technology.

As Ventaris Surgical advances with the support of leading investors, the path ahead promises exciting developments, not just for the company but for patients and healthcare professionals seeking progress in kidney stone treatment methods.